A. Pallis

发表

End points and trial design in geriatric oncology research: a joint European organisation for research and treatment of cancer--Alliance for Clinical Trials in Oncology--International Society Of Geriatric Oncology position article.

Murielle Mauer, Supriya G Mohile, Giuseppe Curigliano, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Instruments for quality of life assessment in patients with inflammatory bowel disease.

A. Pallis, I. Mouzas, 2000, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Second-line paclitaxel/carboplatin versus vinorelbine/carboplatin in patients who have advanced non-small-cell lung cancer pretreated with non-platinum-based chemotherapy: a multicenter randomized phase II study.

S. Agelaki, V. Georgoulias, K. Syrigos, 2011, Clinical lung cancer.

Should all patients who have mesothelioma diagnosed by video-assisted thoracoscopic surgery have their intervention sites irradiated?

M. Nagendran, M. Scarci, A. Pallis, 2011, Interactive cardiovascular and thoracic surgery.

Assessing quality of life in medical trials on patients with inflammatory bowel disease

A. Pallis, I. Mouzas, 2007 .

Current view Assessing quality of life in medical trials on patients with inflammatory bowel disease

A. Pallis, I. Mouzas, 2005 .

Pemetrexed (MTA) compared with erlotinib (ERL) in pretreated patients with advanced non-small cell lung cancer (NSCLC): Results of a randomized phase III Hellenic Oncology Research Group trial.

S. Agelaki, V. Georgoulias, I. Boukovinas, 2010 .

Detection of occult HER2 mRNA-positive tumor cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic relevance

G. Kallergi, D. Mavroudis, V. Georgoulias, 2008, Breast Cancer Research and Treatment.

Circulating HER2 mRNA-positive cells in the peripheral blood of patients with stage I and II breast cancer after the administration of adjuvant chemotherapy: evaluation of their clinical relevance.

S. Agelaki, V. Georgoulias, M. Perraki, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Adjuvant chemotherapy for colon cancer.

A. Pallis, I. Mouzas, 2006, Anticancer research.

Irinotecan plus weekly 5-fluorouracil and leucovorin as salvage treatment for patients with metastatic colorectal cancer: a phase II trial.

S. Agelaki, V. Georgoulias, D. Mavroudis, 2007, Digestive diseases.

Economic analysis of a multicentre, randomised, phase III trial comparing FOLFOXIRI with FOLFIRI in patients with metastatic colorectal cancer in Greece

N. Maniadakis, A. Pallis, V. Fragoulakis, 2007, Current medical research and opinion.

WITHDRAWN: Irinotecan plus Weekly 5-Fluorouracil and Leucovorin as Salvage Treatment for Patients with Metastatic Colorectal Cancer: A Phase II Trial

S. Agelaki, V. Georgoulias, D. Mavroudis, 2007, Digestive Diseases.

Combination of Irinotecan (CPT-11) plus 5-Fluorouracil and Leucovorin (FOLFIRI Regimen) as First Line Treatment for Elderly Patients with Metastatic Colorectal Cancer: A Phase II Trial

S. Agelaki, V. Georgoulias, D. Mavroudis, 2005, Oncology.

Validation of a Reliable Instrument (QUOTE-IBD) for Assessing the Quality of Health Care in Greek Patients with Inflammatory Bowel Disease

I. Vlachonikolis, A. Pallis, I. Mouzas, 2004, Digestion.

Completion of radiotherapy is associated with the Vulnerable Elders Survey-13 score in elderly patients with cancer.

D. Kardamakis, A. Pallis, D. Spyropoulou, 2014, Journal of geriatric oncology.

A phase II trial of erlotinib as front-line treatment in clinically selected patients with non-small-cell lung cancer.

V. Georgoulias, A. Voutsina, S. Agelaki, 2012, Clinical lung cancer.

High prevalence of osteoblastic bone reaction in computed tomography scans of an European Organisation for Research and Treatment of Cancer prospective randomised phase II trial in extensive stage small cell lung cancer.

C. Fink, P. Baas, M. O'Brien, 2012, European journal of cancer.

A multicenter phase I trial of metronomic oral vinorelbine plus cisplatin in patients with NSCLC

V. Georgoulias, I. Varthalitis, A. Pallis, 2011, Cancer Chemotherapy and Pharmacology.

Economic evaluation of docetaxel/gemcitabine versus docetaxel as frontline treatment of patients with advanced/metastatic non-small cell lung cancer in Greece.

N. Maniadakis, A. Pallis, V. Fragoulakis, 2007, Lung cancer.

Economic evaluation of pemetrexed versus erlotinib as second-line treatment of patients with advanced/metastatic non-small cell lung cancer in Greece: a cost minimization analysis.

N. Maniadakis, A. Pallis, V. Fragoulakis, 2012, Lung Cancer.

Phase I study of weekly paclitaxel and liposomal doxorubicin in patients with advanced solid tumours.

S. Agelaki, V. Georgoulias, G. Samonis, 2001, European journal of cancer.

Factors associated with the use of pap smear testing in Greece.

N. Maniadakis, G. Kourlaba, A. Pallis, 2010, Journal of women's health.

Quality of health care in inflammatory bowel disease and its assessment

A. Pallis, I. Mouzas, 2002 .

Patients' perceptions as an indicator of quality of care, in Greek patients with inflammatory bowel disease.

D. Niakas, Petros A Kostagiolas, A. Pallis, 2009, Scandinavian journal of caring sciences.

Central nervous system relapse in patients with breast cancer is associated with advanced stages, with the presence of circulating occult tumor cells and with the HER2/neu status

D. Mavroudis, V. Georgoulias, M. Perraki, 2006, Breast Cancer Research.

Multicenter dose-finding study of concurrent capecitabine and radiotherapy as adjuvant treatment for operable rectal cancer.

V. Georgoulias, D. Mavroudis, J. Souglakos, 2003, International journal of radiation oncology, biology, physics.

Advanced Breast Cancer: Treatment with Docetaxel/Epirubicin

A. Pallis, V. Georgoulias, V. Mavroudis, 2008 .

Mechanisms of resistance to epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small-cell lung cancer: clinical and molecular considerations.

C. Papadimitriou, H. Linardou, D. Bafaloukos, 2011, Current medicinal chemistry.

Lung cancer in never smokers: disease characteristics and risk factors.

K. Syrigos, A. Pallis, 2013, Critical reviews in oncology/hematology.

A Review of Treatment in Non-small-cell Lung Cancer

A. Pallis, 2011 .

Is there a standard regimen for first-line treatment of advanced/metastatic Non-Small-Cell Lung Cancer? What has meta-analyses contributed to today's standard of care.

V. Georgoulias, A. Pallis, 2012, Lung cancer.

Evaluating the physiological reserves of older patients with cancer: the value of potential biomarkers of aging?

H. Wildiers, G. Pawelec, A. Ring, 2014, Journal of geriatric oncology.

EORTC Elderly Task Force and Lung Cancer Group and International Society for Geriatric Oncology (SIOG) experts' opinion for the treatment of non-small-cell lung cancer in an elderly population.

D. Lacombe, C. Gridelli, J. V. van Meerbeeck, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Treatment of small‐cell lung cancer in elderly patients

D. Lacombe, C. Gridelli, F. Shepherd, 2010, Cancer.

DNA repair pathways and their implication in cancer treatment

M. Karamouzis, A. Pallis, 2010, Cancer and Metastasis Reviews.

Targeted therapies in the treatment of advanced/metastatic NSCLC.

D. Lacombe, C. Gridelli, J. V. van Meerbeeck, 2009, European journal of cancer.

Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of NSCLC.

K. Syrigos, A G Pallis, K N Syrigos, 2013, Lung cancer.

‘Classical’ but not ‘other’ mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer

E. Stathopoulos, A. Voutsina, S. Murray, 2007, British Journal of Cancer.

Management of elderly patients with NSCLC; updated expert's opinion paper: EORTC Elderly Task Force, Lung Cancer Group and International Society for Geriatric Oncology.

C. Gridelli, G. Veronesi, C. Faivre-Finn, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

A multicenter randomized phase II study of the irinotecan/gemcitabine doublet versus irinotecan monotherapy in previously treated patients with extensive stage small-cell lung cancer.

V. Georgoulias, S. Agelaki, I. Varthalitis, 2009, Lung cancer.

Targeting tumor neovasculature in non-small-cell lung cancer.

K. Syrigos, A. Pallis, 2013, Critical reviews in oncology/hematology.

Are we treating enough elderly patients with early stage non-small cell lung cancer?

M. Scarci, A. Pallis, 2011, Lung cancer.

Biomarkers of clinical benefit for anti-epidermal growth factor receptor agents in patients with non-small-cell lung cancer

R. Dziadziuszko, D. Fennell, N. Leighl, 2011, British Journal of Cancer.

A phase Ib dose allocation study of oral administration of lucitanib given in combination with fulvestrant in patients with estrogen receptor-positive and FGFR1-amplified or non-amplified metastatic breast cancer

F. Penault-Llorca, F. André, M. Campone, 2019, Cancer Chemotherapy and Pharmacology.

Chemotherapy of advanced non-small-cell lung cancer: current landscape

R. Dziadziuszko, M. O'Brien, A. Pallis, 2013 .

Suggestions, Opinions and Recommendations for the Diagnosis, Management, Treatment and Surveillance of Lung Cancer

J. Dahabreh, S. Murray, C. Kosmas, 2011 .

Molecular networks in respiratory epithelium carcinomas.

M. Karamouzis, A. Papavassiliou, P. Konstantinopoulos, 2010, Cancer letters.

R. Stupp, M. Sprangers, A. Bottomley, 2014, The Lancet. Oncology.

Nutritional status, acute phase response and depression in metastatic lung cancer patients: correlations and association prognosis

D. Mavroudis, V. Georgoulias, Z. Giannousi, 2012, Supportive Care in Cancer.

Assessing health-related quality of life in patients with inflammatory bowel disease, in Crete, Greece

I. Vlachonikolis, A. Pallis, I. Mouzas, 2002, BMC gastroenterology.

The Inflammatory Bowel Disease Questionnaire: A Review of Its National Validation Studies

I. Vlachonikolis, A. Pallis, I. Mouzas, 2004, Inflammatory bowel diseases.

Autonomic imbalance during the day in patients with inflammatory bowel disease in remission. Evidence from spectral analysis of heart rate variability over 24 hours.

P. Vardas, G. Kochiadakis, M. Marketou, 2002, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Quality of Life of Greek Patients with Inflammatory Bowel Disease

I. Vlachonikolis, A. Pallis, I. Mouzas, 2001, Digestion.

Pharmacoeconomic considerations in the treatment of breast cancer

N. Maniadakis, A. Pallis, V. Tsiantou, 2010, ClinicoEconomics and outcomes research : CEOR.

Pixantrone plus rituximab versus gemcitabine plus rituximab in patients with relapsed aggressive B‐cell non‐Hodgkin lymphoma not eligible for stem cell transplantation: a phase 3, randomized, multicentre trial (PIX306)

G. Salles, J. Singer, R. Pettengell, 2019, British journal of haematology.

The Glasgow Prognostic Score (GPS) predicts toxicity and efficacy in platinum-based treated patients with metastatic lung cancer.

Z. Giannousi, P. Vlachostergios, V. Georgoulias, 2012, Lung cancer.

Phase 1 Cohort Expansion of Flotetuzumab, a CD123×CD3 Bispecific Dart® Protein in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

S. Rutella, J. Dipersio, J. Wigginton, 2018, Blood.

A dose escalation study of docetaxel and oxaliplatin combination in patients with metastatic breast and non-small cell lung cancer.

S. Agelaki, D. Mavroudis, V. Georgoulias, 2003, Anticancer research.

Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052).

J. V. van Meerbeeck, A. Price, P. Baas, 2013, European journal of cancer.

Sequential administration of docetaxel followed by maintenance gefitinib, as salvage treatment in patients with advanced NSCLC: a multicenter phase II trial.

S. Agelaki, V. Georgoulias, A. Kalykaki, 2007, Lung cancer.

A multicenter phase II study of sequential vinorelbine and cisplatin followed by docetaxel and gemcitabine in patients with advanced non-small cell lung cancer.

V. Georgoulias, A. Pallis, A. Kotsakis, 2006, Lung cancer.

Instruments for quality of life assessment in patients with gastrointestinal cancer.

A. Pallis, I. Mouzas, 2004, Anticancer research.

Docetaxel versus docetaxel/cisplatin in patients with advanced non-small-cell lung cancer: preliminary analysis of a multicenter, randomized phase III study.

V. Georgoulias, N. Samaras, A. Pallis, 2003, Clinical lung cancer.

Clinical relevance of circulating CK-19 mRNA-positive cells detected during the adjuvant tamoxifen treatment in patients with early breast cancer.

D. Mavroudis, V. Georgoulias, M. Perraki, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical relevance of circulating CK-19 mRNA-positive cells detected during the period of adjuvant tamoxifen treatment in patients with early breast cancer

V. Georgoulias, M. Perraki, M. Kafousi, 2007 .

EORTC workshop on clinical trial methodology in older individuals with a diagnosis of solid tumors.

H. Wildiers, M. Aapro, A. Ring, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Questionnaires and instruments for a multidimensional assessment of the older cancer patient: what clinicians need to know?

D. Lacombe, H. Wildiers, P. Soubeyran, 2010, European journal of cancer.

A randomized phase III study of the docetaxel/carboplatin combination versus docetaxel single-agent as second line treatment for patients with advanced/metastatic Non-Small Cell Lung Cancer

S. Agelaki, V. Georgoulias, K. Syrigos, 2010, BMC Cancer.

A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer.

V. Georgoulias, I. Boukovinas, N. Malamos, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

EORTC elderly task force position paper: approach to the older cancer patient.

D. Lacombe, H. Wildiers, P. Scalliet, 2010, European journal of cancer.

Biweekly Carboplatin Plus Gemcitabine as First-Line Treatment of Elderly Patients With Advanced Squamous Non-Small-cell Lung Cancer: A Multicenter Phase I-II Trial by the Hellenic Oncology Research Group.

V. Georgoulias, G. Rigas, A. Polyzos, 2016, Clinical lung cancer.

Docetaxel vs. vinorelbine in elderly patients with advanced non--small-cell lung cancer: a hellenic oncology research group randomized phase III study.

V. Georgoulias, A. Pallis, N. Vardakis, 2011, Clinical lung cancer.

Molecular detection of HER2 mRNA-positive cells in the peripheral blood of patients with operable breast cancer

G. Kallergi, V. Georgoulias, M. Perraki, 2005 .

A multicenter phase II study of docetaxel, gemcitabine and trastuzumab administration as first-line treatment in patients with advanced breast cancer (ABC) overexpressing HER.

V. Georgoulias, N. Malamos, D. Mavroudis, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term clinical benefit from salvage EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer patients with EGFR wild-type tumors

V. Georgoulias, A. Voutsina, E Lagoudaki, 2018, Clinical and Translational Oncology.

Clinical relevance of circulating CK-19mRNA-positive tumour cells before front-line treatment in patients with metastatic breast cancer

S. Agelaki, V. Georgoulias, M. Perraki, 2012, British Journal of Cancer.

International validation of the EORTC QLQ-ELD14 questionnaire for assessment of health-related quality of life elderly patients with cancer

P. Fayers, S. Wheelwright, W. Chie, 2013, British Journal of Cancer.

EORTC Elderly Task Force experts' opinion for the treatment of colon cancer in older patients.

D. Lacombe, E. Van Cutsem, G. Folprecht, 2010, Cancer treatment reviews.

Attitudes and referral patterns of lung cancer specialists in Europe to Specialized Palliative Care (SPC) and the practice of Early Palliative Care (EPC)

M. O'Brien, H. Charalambous, B. Hasan, 2014, BMC Palliative Care.

Is age a negative prognostic factor for the treatment of advanced/metastatic non-small-cell lung cancer?

C. Gridelli, A. Pallis, 2010, Cancer treatment reviews.

Efficacy and treatment tolerance in older patients with NSCLC: a meta-analysis of five phase III randomized trials conducted by the Hellenic Oncology Research Group.

V. Georgoulias, A. Kalykaki, D. Mavroudis, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Chemotherapy-induced neutropenia as a prognostic factor in patients with advanced non-small cell lung cancer treated with front-line docetaxel-gemcitabine chemotherapy.

S. Agelaki, V. Georgoulias, A. Kalykaki, 2008, Lung cancer.

Management of elderly patients with NSCLC; updated expert's opinion paper: EORTC Elderly Task Force, Lung Cancer Group and International Society for Geriatric Oncology.

C. Gridelli, G. Veronesi, C. Faivre-Finn, 2014 .

Improved validation of the Inflammatory Bowel Disease Questionnaire and development of a short form in Greek patients

I. Vlachonikolis, A. Pallis, I. Mouzas, 2003, American Journal of Gastroenterology.

Pooled Analysis of Elderly Patients with Non-small Cell Lung Cancer Treated with Front Line Docetaxel/Gemcitabine Regimen: The Hellenic Oncology Research Group Experience

S. Agelaki, V. Georgoulias, I. Boukovinas, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer.

D. Mavroudis, V. Georgoulias, I. Boukovinas, 2012 .

Considerations in the design and conduct of clinical drug trials in older cancer patients

A. Pallis, 2012 .

ZD1839, a novel, oral epidermal growth factor receptor-tyrosine kinase inhibitor, as salvage treatment in patients with advanced non-small cell lung cancer. Experience from a single center participating in a compassionate use program.

I. Vlachonikolis, V. Georgoulias, D. Mavroudis, 2003, Lung cancer.

Baseline comprehensive geriatric assessment (CGA) and prediction of toxicity in elderly non-small cell lung cancer (NSCLC) patients receiving chemotherapy.

S. Agelaki, V. Georgoulias, Z. Giannousi, 2011, Journal of Clinical Oncology.

Improved validation of the Inflammatory Bowel Disease Questionnaire and development of a short form in Greek patients.

I. Vlachonikolis, A. Pallis, I. Mouzas, 2003 .

Targeted (and chemotherapeutic) agents as maintenance treatment in patients with metastatic non-small-cell lung cancer: current status and future challenges.

K. Syrigos, A. Pallis, Athanasios G Pallis, 2012, Cancer treatment reviews.